PT - JOURNAL ARTICLE AU - Swathi Muddasani AU - Zar Kotlarsic AU - Kuchalambal Agadi AU - Michelle Jeu AU - Amanda Chavarria AU - Omoyeme Edaki AU - Marcos Sanchez-Gonzalez TI - The efficacy of convalescent plasma therapy in severe COVID-19 patients: a systematic review AID - 10.1183/13993003.congress-2021.PA3768 DP - 2021 Sep 05 TA - European Respiratory Journal PG - PA3768 VI - 58 IP - suppl 65 4099 - http://erj.ersjournals.com/content/58/suppl_65/PA3768.short 4100 - http://erj.ersjournals.com/content/58/suppl_65/PA3768.full SO - Eur Respir J2021 Sep 05; 58 AB - Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease that mainly causes fever, cough, and shortness of breath. Current therapy exploration involves the injection of donated plasma from recovered patients into currently infected individuals through convalescent plasma (CP) therapy. We conducted a systematic literature review for articles relating to the use of CP therapy in adult COVID-19 patients. We identified 29 and 71 articles published from March 2020 through September 2020 from PUBMED and OVID electronic databases. Inclusion and exclusion criteria were set prior to performing the systematic review. A review of articles includes analyses of the findings and results, along with CP's effectiveness, risk-benefits, and adverse effects when administered to moderate to severely symptomatic COVID-19 patients. Results from 11 relevant studies suggest that moderate-severe COVID-19 patients treated with CP therapy have improved clinical conditions, lab results, and length of hospital stay compared to standard of care patients.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3768.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).